Equities research analysts forecast that Crispr Therapeutics AG (NASDAQ:CRSP) will announce sales of $59.43 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Crispr Therapeutics’ earnings, with the highest sales estimate coming in at $76.70 million and the lowest estimate coming in at $14.30 million. Crispr Therapeutics posted sales of $120,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 49,425%. The company is expected to announce its next earnings report on Monday, February 24th.
On average, analysts expect that Crispr Therapeutics will report full-year sales of $272.00 million for the current fiscal year, with estimates ranging from $226.90 million to $289.27 million. For the next year, analysts expect that the business will report sales of $30.04 million, with estimates ranging from $2.03 million to $58.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%.
Several equities analysts recently commented on the stock. Chardan Capital reaffirmed a “buy” rating and set a $72.50 price target on shares of Crispr Therapeutics in a research report on Monday, November 18th. Goldman Sachs Group lifted their price target on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. William Blair raised shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Finally, Roth Capital lifted their target price on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $71.38.
In related news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $390,000. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,118 shares of company stock valued at $3,620,760. Company insiders own 21.40% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Nikko Asset Management Americas Inc. raised its holdings in shares of Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after purchasing an additional 906,006 shares during the period. Orbimed Advisors LLC bought a new position in shares of Crispr Therapeutics in the 3rd quarter worth about $21,167,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after buying an additional 121,176 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after buying an additional 116,540 shares during the period. Finally, Balyasny Asset Management LLC acquired a new position in shares of Crispr Therapeutics in the 2nd quarter valued at about $5,165,000. Hedge funds and other institutional investors own 49.82% of the company’s stock.
CRSP opened at $67.23 on Thursday. Crispr Therapeutics has a 1 year low of $24.56 and a 1 year high of $74.00. The company’s 50 day simple moving average is $63.87 and its 200 day simple moving average is $50.25. The stock has a market capitalization of $3.71 billion, a PE ratio of -19.54 and a beta of 3.31. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: What is a Tariff?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.